Limitations in improving detection of pancreatic adenocarcinoma

Future Oncology

Volumn 5, Issue 5, 2009, Pages 657-668

  Zerón, Hugo Mendieta ^a,b   Flores, Jesús Rey García ^c   Prieto, Martha Liliana Romero ^d  

^a Materno Perinatal Hospital of the State of Mexico ^*  (Mexico)

^b UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^c CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^d Hospital Universitario Fundación Santa Fe   (Colombia)

Author keywords

Pancreatic adenocarcinoma; Screening; Telomerase

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; ERLOTINIB; GEMCITABINE; MUTAGENIC AGENT; PANITUMUMAB; TROXACITABINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHRONIC PANCREATITIS; CIGARETTE SMOKING; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CPG ISLAND; DIABETES MELLITUS; DIARRHEA; DISEASE MARKER; DRUG EFFICACY; DRUG ERUPTION; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; LAPAROSCOPY; LAPAROTOMY; NEEDLE BIOPSY; OBESITY; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ADENOCARCINOMA; DIAGNOSTIC IMAGING; GENETICS; PANCREAS TUMOR; RISK FACTOR;

ADENOCARCINOMA; DIAGNOSTIC IMAGING; HUMANS; PANCREATIC NEOPLASMS; RISK FACTORS;

EID: 69849097550     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.32     Document Type: Review

References (92)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
2. Pinto FG, Curi PR: Mortality due to neoplasms in Brazil (1980/1983/ 1985): grouping by states, behavior and trends. Rev. Saude Publica 25, 276-281 (1991).
3. Donoso SE, Cuello FM: Mortalidad por cáncer en la mujer chilena. Análisis comparativo entre los años 1997 y 2003. Rev. Chil. Obstet. Ginecol. 71, 10-16 (2006).
4. Piñeros M: Incidencia de Cáncer en Colombia: importancia de las fuentes de información en la obtención de cifras estimativas. Rev. Col. de Cancerología 71, 5-14 (2004)
5. Pérez JJ, Martínez MA, del Castillo AL, Villalobos ML, Villalobos GM: Gastrointestinal cancer in four medical centers in Mexico City. A 25-year study. Rev. Gastroenterol. Mex. 71, 460-472 (2006).
6. Farfán G, Cabezas C: Mortality due to digestive and hepatobiliary diseases in Peru. Rev. Gastroenterol. Peru. 22, 310-323 (2002).
7. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J. Clin. 46, 5-27 (1996).
8. Gardner TB, Chari ST: Endoscopic ultrasonography and pancreatic cancer. Minerva Gastroenterol. Dietol. 54, 161-176 (2008).
9. Koliopanos A, Avgerinos C, Farfaras A, Manes C, Dervenis C: Radical resection of pancreatic cancer. Hepatobiliary Pancreat. Dis. Int. 7, 11-18 (2008).
10. Gemmel C, Eickhoff A, Helmstadter L, Riemann JF: Pancreatic cancer screening: state of the art. Expert Rev. Gastroenterol. Hepatol. 3, 89-96 (2009).
11. Otsuki M, Tashiro M: 4. Chronic pancreatitis and pancreatic cancer, lifestyle-related diseases. Intern. Med. 46, 109-113 (2007).
12. Alguacil J, Silverman DT: Smokeless and other noncigarette tobacco use and pancreatic cancer: a case-control study based on direct interviews. Cancer Epidemiol. Biomarkers Prev. 13, 55-58 (2004).
13. Hassan MM, Abbruzzese JL, Bondy ML et al.: Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. Cancer 109, 2547-2556 (2007).
14. Wang F, Gupta S, Holly EA: Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol. Biomarkers Prev. 15, 1458-1463 (2006).
15. Patel AV, Rodriguez C, Bernstein L et al.: Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol. Biomarkers Prev. 14, 459-466 (2005).
16. Li D, Day RS, Bondy ML et al.: Dietary mutagen exposure and risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 16, 655-661 (2007).
17. Soreide K, Immervoll H, Molven A: [Precursors to pancreatic cancer]. Tidsskr. Nor Laegeforen. 126, 905-908 (2006).
18. Jung KW, Kim MH, Lee TY et al.: Clinicopathological aspects of 542 cases of pancreatic cancer: a special emphasis on small pancreatic cancer. J. Korean Med. Sci. 22, S79-S85 (2007).
19. Kopchak VM, Shevkolenko GG, Kopchak KV, Chernyi VV: Anemia in patients with resectable tumour of periampullar zone organs as a risk factor of postoperative complications occurrence and its complex correction. Klin. Khir. 13-15 (2006).
20. Siddiqui A, Heinzerling J, Livingston EH, Huerta S: Predictors of early mortality in veteran patients with pancreatic cancer. Am. J. Surg. 194, 362-366 (2007).
21. Satake K, Takeuchi T: Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas 9, 720-724 (1994).
22. Hess V, Glimelius B, Grawe P et al.: CA 19-19 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 9, 132-138 (2008).
23. Fujioka S, Misawa T, Okamoto T et al.: Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-19 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J. Hepatobiliary. Pancreat. Surg. 14, 539-544 (2007).
24. Palsson B, Masson P, Andrén-Sandberg A: Tumour marker CA 50 levels compared with signs and symptoms in the diagnosis of pancreatic cancer. Eur.J Surg.Oncol. 23, 151-156 (1997).
25. Gandolfi L, Torresan F, Solmi L, Puccetti A: The role of ultrasound in biliary and pancreatic diseases. Eur. J. Ultrasound 16, 141-159 (2003).
26. Sofuni A, Iijima H, Moriyasu F et al.: Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J. Gastroenterol. 40, 518-525 (2005).
27. D'Onofrio M, Zamboni G, Faccioli N, Capelli P, Pozzi MR: Ultrasonography of the pancreas. 4. Contrast-enhanced imaging. Abdom. Imaging 32, 171-181 (2007).
28. Francis IR: Role of CT and MR in detection and staging of pancreatic adenocarcinoma. Cancer Imaging 4, 10-14 (2004).
29. Gritzmann N, Macheiner P, Hollerweger A, Hubner E: CT in the differentiation of pancreatic neoplasms - progress report. Dig. Dis. 22, 6-17 (2004).
30. Grenacher L, Klauss M: Computed tomography of pancreatic tumors. Radiologe 49, 107-123 (2009).
31. Jin Z, Li X, Cai L: Assessing the resectability of pancreatic ductal adenocarcinoma: comparision of dual-phase helical CT arterial portography with conventional angiography. Chin. Med. Sci. J. 16, 40-45 (2001).
32. Valls C, Andia E, Sanchez A et al.: Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am. J. Roentgenol. 178, 821-826 (2002).
33. Chandarana H, Babb J, Macari M: Signal characteristic and enhancement patterns of pancreatic adenocarcinoma: evaluation with dynamic gadolinium enhanced MRI. Clin. Radiol. 62, 876-883 (2007).
34. Schima W: MRI of the pancreas: tumours and tumour-simulating processes. Cancer Imaging 6, 199-203 (2006).
35. Schima W, Ba-Ssalamah A, Goetzinger P, Scharitzer M, Koelblinger C: State-of-the-art magnetic resonance imaging of pancreatic cancer. Top Magn. Reson. Imaging 18, 421-429 (2007).
36. Sahni VA, Mortele KJ: Magnetic resonance cholangiopancreatography: current use and future applications. Clin. Gastroenterol. Hepatol. 6, 967-977 (2008).
37. Fusaroli P, Caletti G: Endoscopic ultrasonography: current clinical role. Eur. J. Gastroenterol. Hepatol. 17, 293-301 (2005).
38. Horwhat JD, Gerke H, Acosta RD, Pavey DA, Jowell PS: Focal or diffuse 'fullness' of the pancreas on CT. Usually benign, but EUS plus/minus FNA is warranted to identify malignancy. JOP 10, 37-42 (2009).
39. Tian YT, Wang CF, Wang GQ et al.: Prospective evaluation of the clinical significance of ultrasonography, helical computed tomography, magnetic resonance imaging and endoscopic ultrasonography in the assessment of vascular invasion and lymph node metastasis of pancreatic carcinoma. Zhonghua Zhong. Liu Za Zhi. 30, 682-685 (2008).
40. Delbeke D, Pinson CW: Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J. Hepatobiliary Pancreat. Surg. 11, 4-10 (2004).
41. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 54(Suppl. 5), v1-v16 (2005).
42. de IE, López-Cervantes M, Arredondo A, Robles-Diaz G: Likelihood ratios of clinical, laboratory and image data of pancreatic cancer: Bayesian approach. J. Eval. Clin. Pract. 15, 62-68 (2009).
43. Wang P, Li ZS, Liu F et al.: Risk factors for ERCP-related complications: a prospective multicenter study. Am. J. Gastroenterol. 104, 31-40 (2009).
44. Racz I, Rejchrt S, Hassan M: Complications of ERCP: ethical obligations and legal consequences. Dig. Dis. 26, 49-55 (2008).
45. Schick V, Franzius C, Beyna T et al.: Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur. J. Nucl. Med. Mol. Imaging 35, 1775-1785 (2008).
46. Hartwig W, Schneider L, Diener MK et al.: Preoperative tissue diagnosis for tumours of the pancreas. Br. J. Surg. 96, 5-20 (2009).
47. Lai R, Stanley MW, Bardales R, Linzie B, Mallery S: Endoscopic ultrasound-guided pancreatic duct aspiration: diagnostic yield and safety. Endoscopy 34, 715-720 (2002).
48. Yang GC: Ultrasound-guided fine needle aspiration of the pancreas: endoscopic vs. percutaneous approach. Acta Cytol. 52, 521-522 (2008).
49. Matsubara J, Okusaka T, Morizane C, Ikeda M, Ueno H: Ultrasound-guided percutaneous pancreatic tumor biopsy in pancreatic cancer: a comparison with metastatic liver tumor biopsy, including sensitivity, specificity, and complications. J. Gastroenterol. 43, 225-232 (2008).
50. Savides TJ, Donohue M, Hunt G et al.: EUS-guided FNA diagnostic yield of malignancy in solid pancreatic masses: a benchmark for quality performance measurement. Gastrointest. Endosc. 66, 277-282 (2007).
51. Sperti C, Pasquali C, Di PF et al.: Percutaneous CT-guided fine needle aspiration cytology in the differential diagnosis of pancreatic lesions. Ital. J. Gastroenterol. 26, 126-131 (1994).
52. Andersson R, Vagianos C, Williamson R: Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB (Oxford) 6, 5-12 (2004).
53. Hruban RH, Takaori K, Klimstra DS et al.: An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am. J. Surg. Pathol. 28, 977-987 (2004).
54. Saif MW, Karapanagiotou L, Syrigos K: Genetic alterations in pancreatic cancer. World J. Gastroenterol. 13, 4423-4430 (2007).
55. Sahani DV, Lin DJ, Venkatesan AM et al.: Multidisciplinary approach to diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas. Clin. Gastroenterol. Hepatol. 7(3), 259-269 (2008).
56. Hruban RH, Maitra A, Kern SE, Goggins M: Precursors to pancreatic cancer. Gastroenterol. Clin. North Am. 36, 831-849, vi (2007).
57. Maitra A, Hruban RH: Pancreatic cancer. Annu. Rev. Pathol. 3, 157-188 (2008).
58. Jones S, Zhang X, Parsons DW et al.: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
59. Wehrum D, Grutzmann R, Hennig M, Saeger HD, Pilarsky C: Recent patents concerning diagnostic and therapeutic applications of aberrantly methylated sequences in pancreatic cancer. Recent Pat. DNA Gene Seq. 2, 97-106 (2008).
60. Omura N, Li CP, Li A et al.: Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol.Ther. 7, 1146-1156 (2008).
61. Peng B, Fleming JB, Breslin T et al.: Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. Clin. Cancer Res. 8, 3628-3638 (2002).
62. Nomoto S, Kinoshita T, Mori T et al.: Adverse prognosis of epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic cancer. Br. J. Cancer 98, 1690-1695 (2008).
63. Maitra A, Adsay NV, Argani P et al.: Multicomponent ana lysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod. Pathol. 16, 902-912 (2003).
64. Liang JJ, Kimchi ET, Staveley-O'Carroll KF, Tan D: Diagnostic and prognostic biomarkers in pancreatic carcinoma. Int. J. Clin. Exp. Pathol. 2, 1-10 (2009).
65. Feldmann G, Beaty R, Hruban RH, Maitra A: Molecular genetics of pancreatic intraepithelial neoplasia. J. Hepatobiliary. Pancreat. Surg. 14, 224-232 (2007).
66. Gerdes B, Ramaswamy A, Ziegler A et al.: p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an ana lysis of p16INK4a, p53, MDM2, an Rb. Ann. Surg. 235, 51-59 (2002).
67. Hashimoto Y, Murakami Y, Uemura K et al.: Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. J. Gastrointest. Surg. 12, 17-28 (2008).
68. Uehara H, Nakaizumi A, Iishi H et al.: In situ telomerase activity in pancreatic juice may discriminate pancreatic cancer from other pancreatic diseases. Pancreas 36, 236-240 (2008).
69. Zhou GX, Huang JF, Zhang H, Chen JP: Diagnosis of pancreatic cancer by cytology and telomerase activity in exfoliated cells obtained by pancreatic duct brushing during endoscopy. Hepatobiliary Pancreat. Dis. Int. 6, 308-311 (2007).
70. Yang L, Mao H, Cao Z et al.: Molecular imaging of pancreatic cancer in a preclinical animal tumor model using targeted multifunctional nanoparticles. Gastroenterology 136(5), 1514-1525 e2 (2009).
71. Eck W, Craig G, Sigdel A et al.: PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue. ACS Nano. 2, 2263-2272 (2008).
72. Peracaula R, Barrabes S, Sarrats A, Rudd PM, de Llorens R: Altered glycosylation in tumours focused to cancer diagnosis. Dis. Markers 25, 207-218 (2008).
73. Schmidt U, Simunec D, Piso P, Klempnauer J, Schlitt HJ: Quality of life and functional long-term outcome after partial pancreatoduodenectomy: pancreatogastrostomy versus pancreatojejunostomy. Ann. Surg. Oncol. 12, 467-472 (2005).
74. Wagner M, Kulli C, Friess H, Seiler CA, Buchler MW: Surgery of pancreatic carcinoma. Swiss. Surg. 6, 264-270 (2000).
75. Dineen SP, Roland CL, Schwarz RE: Pancreatoduodenectomy with or without pyloric preservation: a clinical outcomes comparison. HPB Surg. 2008, 719459 (2008).
76. Glanemann M, Shi B, Liang F et al.: Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery? World J. Surg.Oncol. 6, 123 (2008).
77. Reddy SK, Tyler DS, Pappas TN, Clary BM: Extended resection for pancreatic adenocarcinoma. Oncologist 12, 654-663 (2007).
78. Damaraju VL, Bouffard DY, Wong CK et al.: Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer. BMC Cancer 7, 121 (2007).
79. Papageorgio C, Perry MC: Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Cancer Invest. 25, 647-657 (2007).
80. El FJ, Su Y, Buchler P et al.: PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer. Cancer 110, 1457-1468 (2007).
81. Heeger S: Targeted therapy of the epidermal growth factor receptor in the treatment of pancreatic cancer. Recent Results Cancer Res. 177, 131-136 (2008).
82. Welch SA, Moore MJ: Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer. Future Oncol. 3, 247-254 (2007).
83. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS: The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin. Cancer Res. 14, 5142-5149 (2008).
84. Li X, Roginsky AB, Ding XZ et al.: Review of the apoptosis pathways in pancreatic cancer and the anti-apoptotic effects of the novel sea cucumber compound, Frondoside A. Ann. NY Acad. Sci. 1138, 181-198 (2008).
85. Tonini G, Pantano F, Vincenzi B et al.: Molecular prognostic factors in patients with pancreatic cancer. Expert Opin. Ther. Targets 11, 1553-1569 (2007).
86. Canto MI: Screening for pancreatic neoplasia in high-risk individuals: who, what, when, how? Clin. Gastroenterol. Hepatol. 3, S46-S48 (2005).
87. Klapman J, Malafa MP: Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control 15, 280-287 (2008).
88. Sawabu N, Watanabe H, Yamaguchi Y, Ohtsubo K, Motoo Y: Serum tumor markers and molecular biological diagnosis in pancreatic cancer. Pancreas 28, 263-267 (2004).
89. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J. Clin. 50, 7-33 (2000).
90. Windsor JA: An update on familial pancreatic cancer and the management of asymptomatic relatives. HPB (Oxford) 9, 4-7 (2007).
91. Lowenfels AB, Maisonneuve P: Epidemiology and risk factors for pancreatic cancer. Best. Pract. Res. Clin. Gastroenterol. 20, 197-209 (2006).
92. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).